The Plasminogen Activator Inhibitor-1 Gene Polymorphism in Determining the Risk of Pediatric Ischemic Stroke − Case Control and Family-Based Study

Abstract

Pediatric ischemic stroke, though relatively rare, remains an important medical problem since 20−40% of patients have recurrent strokes and 50−85% of them suffer from long-term neurological deficits. Approximately 20−50% of the affected children have prothrombotic disorders, therefore upon looking for possible genetic causes of the disease we focused on the plasminogen activator inhibitor (PAI-1) − the major inhibitor of fibrinolysis. The aim of the present study was to investigate a possible association between the -675_-674insG PAI-1 gene polymorphism and pediatric ischemic stroke. The study population consisted of 343 individuals: 70 children with ischemic stroke, 140 their biological parents and 133 control children. The PAI-1 gene polymorphism was genotyped using the restriction fragment length polymorphism and was visualized by AgNO₃ staining. The transmission/disequilibrium test showed exactly the same transmission of alleles from parents to the affected children (37:37). The case-control model also did not reveal any statistical significance in alleles and genotypes distribution between patients and control children. The obtained results suggest that the 4 G/5 G polymorphism of the PAI-I gene is not a risk factor of ischemic stroke in Polish children.

Key words

ischemic stroke - children - gene polymorphism - plasminogen activator inhibitor-1

• References

• 1 Adamski MG, Turaj W, Slowik A et al A-G-4 G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C and -675 4 G/5 G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta Neurol Scand 2009; 120: 94-100
• 2 Attia J, Thakkinstian A, Wang Y et al The PAI-1 4 G/5 G gene polymorphism and ischemic stroke: an association study and meta-analysis. J Stroke Cerebrovasc 2007; 16: 173-179
• 3 Barnes C, Deveber G. Prothrombotic abnormalities in childhood ischemic stroke. Thromb Res 2006; 118: 67-74
• 4 Dawson SJ, Wiman B, Hamsten A et al The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745
• 5 Friedman N. Pediatric stroke: past, present and future. Adv Pediatr 2009; 56: 271-299
• 6 Hoekstra T, Geleijnse JM, Kluft C et al 4 G/4 G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 2003; 34: 2822-2828
• 7 Jood K, Ladenvall P, Tjarnlund-Wolf A et al Fibrinolytic gene polymorphism and ischemic stroke. Stroke 2005; 36: 2077-2081
• 8 Komitopoulou A, Platokouki H, Kapsimali Z et al Mutations and polymorphisms in genes affecting hemostasis proteins and homocysteine metabolism in children with arterial ischemic stroke. Cerebrovasc Dis 2006; 2: 13-20
• 9 Kopyta I, Emich-Widera E, Marszał E. Brain ischemic stroke in children- case analysis with the focus on risk factors. Child Neurology 2002; 11: 21-27
• 10 Kopyta I, Sarecka-Hujar B, Emich-Widera E et al Association between lipids and fibrynogen levels and ischemic stroke in the population of the Polish children with arteriopathy and cardiac disorders. Wiad Lek 2010; 63: 17-23
• 11 Mackay MT, Gordon A. Stroke in children. Aust Fam Physician 2007; 36: 896-902
• 12 Margaglione M, Di Minno G, Grandone E et al Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb Vasc Biol 1994; 14: 1741-1745
• 13 Nowak-Göttl U, Sträter R, Heinecke A et al Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94: 3678-3682
• 14 Nowak-Göttl U, Sträter R, Kosch A et al The plasminogen activator inhibitor (PAI)-1 promoter 4 G/4 G genotype is not associated with ischemic stroke in a population of German children. Eur J Haematol 2001; 66: 57-62
• 15 Pilarska E, Lemka M, Bakowska A. Prothrombotic risk factors in ischemic stroke and migraine in children. Acta Neurol Scand 2006; 114: 13-16
• 16 Pilarska E, Lemka M, Bakowska A. Thrombomodulin and antibeta2-glycoprotein I in stroke in children. Med Sci Monit 2010; 16: CR348-CR351
• 17 Sans M, Tassies D, Pellise M et al The 4 G/4 G genotype of the 4 G/5 G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn’s disease. Aliment Pharmacol Ther 2003; 17: 1039-1047
• 18 Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993; 52: 506-516
• 19 Tsantes AE, Nikolopoulos GK, Bagos PG et al The effect of the plasminogen activator inhibitor-1 4 G/5 G polymorphism on the thrombotic risk. Thromb Res 2008; 122: 736-742
• 20 Wiklund PG, Nilsson L, Ardnor S et al Plasminogen activator inhibitor-14 G/5 G and risk of stroke. Replicated findings in two nested case- control studies based on independent cohorts. Stroke 2005; 36: 1661-1665
• 21 Zenz W, Bodó Z, Plotho J et al Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke. Thromb Haemost 1998; 80: 763-766
• 22 Żak I, Sarecka Hujar B, Kopyta I et al The allele of the 677C>T polymorphism of methylenentetrahydrofolate reductase gene is associated with an incresed risk of ischemic stroke in Polish children. J Child Neurol 2009; 24: 1262-1267